Bolar re-shipping
Executive Summary
Company announces approval from FDA to begin remarketing products withheld from the market since mid-August. The firm halted shipments in August after FDA complained of formulation changes without appropriate NDA filings ("The Pink Sheet" Aug. 26, p. 3).